Drug Trial Radar · NCT03718065
Impact of Lofexidine on Stress, Craving and Opioid Use
Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
112
Actual
Start
Jun 26, 2019
Primary completion
Jan 30, 2024
Study completion Jan 30, 2024
Sponsor
- Lead sponsor
- Medical University of South CarolinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institutes of Health (NIH); National Institute on Drug Abuse (NIDA)
- First posted
- Oct 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Individuals with opioid use disorder who are stabilized on buprenorphine or methadone will be randomly assigned to receive placebo or lofexidine for 5 weeks. At the end of five weeks, they will complete a human laboratory stress task and scripted opioid imagery task. Throughout the study a CREMA app (Cue Reactivity Ecological Momentary Assessment) will be used to monitor stress, craving and use in the natural environment.
Conditions
- Opioid-use Disorder
- Opiate Dependence
Interventions
LofexidineDrug
Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist.
PlaceboDrug
Placebo comparator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Drug Cue+ Stressor Induced CravingTime frame: Pre- Cue and 0, 5, 30 and 60 minutes Post-Cue 5 weeks Post- Baseline; Pre-TSST and 0, 5, 30 and 60 minutes Post-TSST 5 weeks Post-Baseline
- Drug Cue+ Stressor Induced Stress ResponseTime frame: Pre- Cue and 0, 5, 30 and 60 minutes Post-Cue 5 weeks Post- Baseline; Pre-TSST and 0, 5, 30 and 60 minutes Post-TSST 5 weeks Post-Baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of South Carolina
Charleston, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.